| Name | Title | Contact Details |
|---|
Alaunos is a clinical stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. With our robust and innovative discovery engine, we strike cancer at its core by engineering cell therapies that target neoantigens arising from genomic mutations. We have developed proprietary, rapid, cost-effective solutions to deliver tumor-specific killer T cells to large cancer patient populations with unmet clinical need. We are based in Houston, TX, home to the largest medical center in the world; and in a state with no state income tax and a low cost of living. For more information about Alaunos, please visit www.alaunos.com. Click on the Careers tab of our web page to join our exciting team and help make a difference in the lives of cancer patients and their families.
Main OfficeReaction Design is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Cartography Biosciences is focused on developing tumor-selective therapeutics that are based on a unique genomics and computational platform. Cartography`s platform integrates data from proprietary sample sourcing relationships, an industry-leading comprehensive reference atlas, and our target identification algorithms to identify the cells of interest and the single or pairs of targets that are most specific to the intended target cells. Cartography is unlocking the full potential of immunotherapy by discovering and developing therapeutics as precise as their targets. To learn more about Cartography and our mission to treat every patient with cancer.
CerFlux Personalized Medicine aims to reduce the pain, reduce the discomfort, and reduce the cost of cancer treatment.
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum`s proprietary product engine, FulcrumSeekâ„¢, identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta-thalassemia into Phase 1 clinical development.